Early gene expression of acute myeloid leukemia in response to chemotherapy

Expert Review of Anticancer Therapy

Volumn 7, Issue 5, 2007, Pages 741-751

  Anensen, Nina ^a   Øyan, Anne M ^a,b   Huseby, Sjur ^a   Kalland, Karl Henning ^a,b   Bruserud, Øystein ^a   Gjertsen, Bjørn T ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

AML; Gene expression; In vivo chemotherapy response; P53

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CD135 ANTIGEN; CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEAT SHOCK PROTEIN 90; IDARUBICIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; PROTEIN BAX; PROTEIN KINASE C DELTA; PROTEIN MDM2; PROTEIN P23; PROTEIN P53; RAPAMYCIN; RETINOIC ACID; UNINDEXED DRUG; VINCRISTINE; ANTHRACYCLINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA MICROARRAY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FOLLOW UP; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSCRIPTION; HAIR LOSS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LOW DRUG DOSE; MUCOSA INFLAMMATION; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; DRUG EFFECT; DRUG MONITORING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DRUG MONITORING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34248585890     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.5.741     Document Type: Review

References (80)

1. Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 62-86 (2001).
2. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92(7), 2322-2333 (1998).
3. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 18(2), 115-136 (2004).
4. Schoch C, Haferlach T, Haase D et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br. J. Haematol. 112(1), 118-126 (2001).
5. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325-4336 (2002).
6. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 368(9550), 1894-1907 (2006).
7. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene 19(21), 2511-2522 (2000).
8. Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB. Control of myeloid differentiation and survival by Stats. Oncogene 19(21), 2612-2618 (2000).
9. Platanias LC. MAP kinase signaling pathways and hematologic malignancies. Blood 101(12), 4667-4679 (2003).
10. Hayakawa F, Towatari M, Kiyoi H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19(5), 624-631 (2000).
11. Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118(2), 217-228 (2004).
12. Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109(6), 2589-2596 (2006).
13. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 106(4), 1154-1163 (2005).
14. Falini B, Mecucci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352(3), 254-266 (2005).
15. Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10(12), 1911-1918 (1996).
16. Wheatley K, Burnett AK, Goldstone AH et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br. J. Haematol. 107(1), 69-79 (1999).
17. Schoch C, Kohlmann A, Schnittger S et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc. Natl Acad. Sci. USA 99(15), 10008-10013 (2002).
18. Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350(16), 1617-1628 (2004).
19. Bullinger L, Valk PJ. Gene expression profiling in acute myeloid leukemia. J. Clin. Oncol. 23(26), 6296-6305 (2005).
20. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res. 12(13), 3985-3992 (2006).
21. Oyan AM, Bo TH, Jonassen I, Gjertsen BT, Bruserud O, Kalland KH. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. Int. J. Oncol. 28(5), 1065-1080 (2006).
22. Oyan AM, Bo TH, Jonassen I et al. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry B Clin. Cytom. 64(1), 18-27 (2005).
23. Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics 17(4), 369-370 (2001).
24. Breitling R, Amtmann A, Herzyk P. Iterative Group Analysis (iGA): a simple tool to enhance sensitivity and facilitate interpretation of microarray experiments. BMC Bioinformatics 5, 34 (2004).
25. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999).
26. Bullinger L, Doner H, Pollack JR. Genomics in myeloid leukemias: an array of possibilities. Rev. Clin. Exp. Hematol. 9(1), E2 (2005).
27. Haferlach T, Kohlmann A, Kern W, Hiddemann W, Schnittger S, Schoch C. Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin. Hematol. 40(4), 281-295 (2003).
28. Valk PJ, Delwel R, Lowenberg B. Gene expression profiling in acute myeloid leukemia. Curr. Opin. Hematol. 12(1), 76-81 (2005).
29. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350(16), 1605-1616 (2004).
30. Kern W, Haferlach T, Schoch C et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101(1), 64-70 (2003).
31. Heuser M, Wingen LU, Steinemann D et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90(11), 1484-1492 (2005).
32. Wagner W, Ansorge A, Wirkner U et al. Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genomewide analysis. Blood 104(3), 675-686 (2004).
33. Baldus CD, Tanner SM, Kusewitt DF et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp. Hematol. 31(11), 1051-1056 (2003).
34. Kanda Y, Hamaki T, Yamamoto R et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 88(11), 2529-2533 (2000).
35. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11), 1294-1300 (2006).
36. Hovland R, Gjertsen BT, Bruserud O. Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. Leuk. Lymphoma 43(10), 2027-2029 (2002).
37. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341(14), 1051-1062 (1999).
38. Weinstein HJ, Mayer RJ, Rosenthal DS et al. Treatment of acute myelogenous leukemia in children and adults. N. Engl. J. Med. 303(9), 473-478 (1980).
39. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl. J. Med. 331(14), 896-903 (1994).
40. Giles GI, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. 1(4), 383-394 (2005).
41. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 98(4), 913-924 (2001).
42. Cros E, Jordheim L, Dumontet C, Galmarini CM. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk. Lymphoma 45(6), 1123-1132 (2004).
43. Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D. Activation of protein kinase Cδ in human myeloid leukemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood 87(5), 1990-1996 (1996).
44. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15(6), 875-890 (2001).
45. Druker BJ, Guithot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006).
46. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat. Med. 2(5), 561-566 (1996).
47. Gale RE, Hills R, Kottaridis PD et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106(10), 3658-3665 (2005).
48. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105(1), 54-60 (2005).
49. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4(11), 1540-1549 (2005).
50. Recher C, Beyne-Rauzy O, Demur C et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105(6), 2527-2534(2005).
51. Tallman MS. New agents for the treatment of acute myeloid leukemia. Best Pract. Res. Clin. Haematol. 19(2), 311-320 (2006).
52. Mueller BU, Pabst T, Fos J et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU. 1 expression. Blood 107(8), 3330-3338 (2006).
53. Castaigne S, Daniel MT, Tilly H, Herait P, Degos L. Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood 62(1), 85-86 (1983).
54. Gausdal G, Gjertsen BT, Fladmark KE, Demol H, Vandekerckhove J, Doskeland SO. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia 18(12), 1989-1996 (2004).
55. Gjertsen BT, Doskeland SO. Protein phosphorylation in apoptosis. Biochim. Biopbys. Acta 1269(2), 187-199 (1995).
56. Gjertsen BT, Cressey LI, Ruchaud S, Houge G, Lanotte M, Doskeland SO. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. J. Cell Sci. 107(Pt 12), 3363-3377 (1994).
57. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 98-117 (2004).
58. Selvaraj A, Prywes R. Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent. BMC Mol. Biol. 5, 13 (2004).
59. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell 14(3), 277-287 (2004).
60. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2(8), 594-604 (2002).
61. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 18(45), 6135-6144 (1999).
62. Rosenwald A, Chuang EY, Davis RE et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104(5), 1428-1434 (2004).
63. Wattel E, Preudhomme C, Hecquet B et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84(9), 3148-3157 (1994).
64. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F, Lubbert M. Mechanisms of p53 alteration in acute leukemias. Leukemia 8(10), 1673-1681 (1994).
65. Fenaux P, Preudhomme C, Quiquandon I et al. Mutations of the P53 gene in acute myeloid leukaemia. Br. J Haematol. 80(2), 178-183 (1992).
66. Wojcik I, Szybka M, Golanska E et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma 52(4), 318-324 (2005).
67. Fenaux P, Jonveaux P, Quiquandon I et al. p53 gene mutations in acute myeloid leukemia with 17p monosomy Blood 78(7), 1652-1657 (1991).
68. Ben-Yehuda D, Krichevsky S, Caspi O et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88(11), 4296-4303(1996).
69. Cario G, Stanulla M, Fine BM et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105(2), 821-826 (2005).
70. Holleman A, Cheok MH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351(6), 533-542 (2004).
71. Zaza G, Cheok M, Yang W et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106(5), 1778-1785 (2005).
72. Mirza A, Wu Q, Wang L et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22 (23), 3645-3654 (2003).
73. Cawley S, Bekiranov S, Ng HH et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116(4), 499-509 (2004).
74. Wei CL, Wu Q, Vega VB et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124(1), 207-219 (2006).
75. Kristensen VN, Edvardsen H, Tsalenko A et al. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc. Natl Acad. Sci. USA 103(20), 7735-7740 (2006).
76. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 65(13), 5481-5484 (2005).
77. Gob BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur. J Surg. Oncol. 32(9), 961-963 (2006).
78. 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res. 25(6C), 4591-4594 (2005).
79. Myers CE, Chabner BA. Anthracyclines. In: Cancer Chemotherapy: Principles and Practice. Chabner BA, Collins JM (Eds). Lippincott Williams & Wilkins, PA, USA 356-381 (1990).
80. Cheok MH, Yang W, Pui CH et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat. Genet. 34(1), 85-90 (2003).